Paragonix Upgrades SherpaPak Cardiac Transport with TempLock for Longer-Distance Heart Transplants
Event summary
- Paragonix introduced TempLock™ temperature stabilization to its SherpaPak® Cardiac Transport System, enhancing temperature stability for longer-distance heart transplants.
- TempLock maintains 4-8°C over extended durations, addressing increasing donor heart ischemic times in the U.S.
- SherpaPak has shown improved survival outcomes in heart transplants compared to traditional ice storage.
- The upgrade was unveiled at ISHLT 2026, with Paragonix emphasizing real-world transport conditions.
The big picture
Paragonix’s TempLock upgrade reflects the growing demand for advanced organ preservation solutions as transplant programs face longer ischemic times. The innovation aligns with broader industry trends toward precision engineering in medical devices, particularly in organ transplantation. As a Getinge company, Paragonix leverages its parent’s resources to push the boundaries of clinical outcomes in heart transplantation.
What we're watching
- Clinical Adoption
- How quickly transplant programs will integrate TempLock into their protocols, given the shift toward longer-distance procurements.
- Competitive Response
- Whether competitors will accelerate their own temperature stabilization technologies to match Paragonix’s innovation.
- Regulatory Scrutiny
- The pace at which regulatory bodies may review or approve extended preservation times enabled by TempLock.
Our editorial coverage: